Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EPS (Weighted Average and Diluted) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.38 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 53.09% to -$0.38 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.44 through Dec 2025, up 29.48% year-over-year, with the annual reading at -$2.43 for FY2025, 29.97% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.38 at Pliant Therapeutics, up from -$0.43 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.38 in Q4 2025, with the low at -$0.95 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.72, with a median of -$0.7 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 59.57% in 2021, then soared 54.74% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.68 in 2021, then fell by 5.88% to -$0.72 in 2022, then grew by 4.17% to -$0.69 in 2023, then dropped by 17.39% to -$0.81 in 2024, then soared by 53.09% to -$0.38 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.38, -$0.43, and -$0.71 for Q4 2025, Q3 2025, and Q2 2025 respectively.